| Patent application number | Description | Published |
|---|
| 20090105208 | Substituted Piperazines as CB1 Antagonists - Compounds of Formula (I): | 04-23-2009 |
| 20100029607 | Substituted Piperazines as CB1 Antagonists - Compounds of Formula (I): | 02-04-2010 |
| 20100249144 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS - Compounds of Formula (I) or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB | 09-30-2010 |
| 20100286160 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS - Compounds of Formula (I): or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions. | 11-11-2010 |
| 20120108505 | THIOPHENES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE - The present invention relates to compounds of the general formula (I): wherein R | 05-03-2012 |
| 20120178789 | NOVEL PYRROLIDINES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE - The present invention relates to compounds of the general formula: (I) wherein ring B, R | 07-12-2012 |
| 20120183563 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE - In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): (I) and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds stereoisomers, wherein each of R | 07-19-2012 |
| 20120189642 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE - In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (a) and include tautomers, solvates, prodrugs, esters, and deuterates thereof, and pharmaceutically acceptable salts of said compounds, tautomers, solvates, prodrugs, esters, and deuterates, wherein each of R | 07-26-2012 |
